May 17, 2020

Auris Health seeks to transform endoscopic operations through surgical robotics

Technology
surgery
Technology
surgery
Catherine Sturman
3 min
Monarch controller
Auris Health has received Food and Drug Administration (FDA) clearance in the US for the company’s Monarch Platform, ushering in a new era of medical...

Auris Health has received Food and Drug Administration (FDA) clearance in the US for the company’s Monarch Platform, ushering in a new era of medical intervention.

Auris Health is pioneering the next era of medical intervention by developing platforms that enhance physician capabilities, enhance minimally invasive techniques, and create new categories of care that redefine optimal patient outcomes.

The company is transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. Every element is driven by patient-specific design aimed at maintaining the integrity of the human body, without the need to create incisions at any stage.

Backed by leading technology investors including Mithril Capital Management, Lux Capital, Coatue Management, and Highland Capital, the company has launched the Monarch Platform, which is set to transform endoscopy.

The use of small cameras and tools enter the body through its natural openings and are operated via a controller, influenced by the modern gaming console, Xbox.

Auris’ first targeted disease state is lung cancer. The FDA has cleared the platform for diagnostic and therapeutic bronchoscopic procedures, with the aim to provide a more-accurate diagnosis, and eventually treatment of small and hard-to-reach nodules in the periphery of the lung.

Founded and led by surgical robotics pioneer Frederic Moll, Auris has raised more than $500 million in equity capital.

See also

“Technology has advanced significantly since the development of the earliest robotics platforms used in medicine,” explained Dr Moll, Chief Executive Officer at Auris Health.

“The Monarch Platform is designed to address the limitations of current technology with the introduction of a new era of flexible robotics. With this FDA clearance, we intend to deliver on the promise of improving patient care, starting with earlier and more accurate diagnosis of pulmonary nodules. We envision additional uses for the technology across future endoscopic clinical indications.”

Lung cancer is the leading cause of cancer deaths worldwide. More patients die every year from the disease than from prostate, breast, and colon cancers combined. More than 90% of people diagnosed with lung cancer do not survive, due to often being found in its advanced stages.

Whilst there are a variety of diagnostic options available for lung cancer, all have limitations in accuracy, safety, or invasiveness. This can lead to false positives, false negatives, or side effects such as pneumothorax (collapsed lung) and haemorrhage, which could increase health care costs and extend hospital stays.

“Four hundred fifty people die every day in the United States due to lung cancer. It is the number one cancer killer of both men and women in the world,” commented Michael Simoff, Managing Director of Interventional Pulmonology at Henry Ford Health System in Detroit, Michigan.

“Lung cancer screening has given us an opportunity diagnose cancer early and have a chance to cure it. The development of new advanced technology, like the Monarch Platform, could allow us the opportunity to make the diagnosis early, which translates directly to saving lives.”

The Monarch Platform is a revolutionary flexible endoscopic technology that holds promise to beat lung cancer by allowing physicians to diagnose, and eventually treat, hard-to-reach, small peripheral nodules with greater precision than ever before.

It utilises a familiar controller-like interface that physicians use to navigate the flexible robotic endoscope to the periphery of the lung with improved reach, vision, and control. Combining traditional endoscopic views into the lung with computer-assisted navigation based on 3D models of the patient’s own lung anatomy, the Monarch Platform provides physicians with continuous bronchoscope vision throughout the entire procedure.

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article